Immunomodulatory oligonucleotide IMT504 induces a marked recovery in a type I diabetes animal model

A. D. MONTANER; M. S. BIANCHI; V CALVO; A CHASSEING; N. LAGO; C. LIBERTUN; V. A. LUX-LANTOS

Río de Janeiro

Congreso; Advanced Technologies & Treatments for Diabetes - Latin American; 2012

Sociedade Brasileira de Diabetes

Immunomodulatory oligonucleotides (im-ODNs) are synthetic molecules that stimulate the innate immune system. We have identified a new ODN-family named PyNTTTTGT. Unlike other im-ODNs, its prototype IMT504 promotes tissue repair in experimental models of bone injury, peripheral nerve crush and pancreatic insult by stimulating progenitor cells. Here, we evaluated the effect of IMT504 on a type I diabetes model. Balb/C-mice were daily ip-injected with STZ (40mg/kg) for 5 days. Animals with glycaemia 250 mg/dl were daily sc-injected with 20 doses of IMT504 (20mg/kg/dose) and followed for 60-days. A second group were treated as above, but killed after two consecutive decreases in glycaemia (2-5 doses). IMT504 induced a decline in blood glucose in 88% of treated-mice. At day-60 glycaemia (mg/dl) were: Control+Saline: 130±20, Control+IMT504: 115±28, STZ+Saline: 557±49, STZ+IMT504: 278±112 (p